Free Republic 2nd Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $41,910
51%  
Woo hoo!! And we're now over 51%!! Thank you all very much!! God bless.

Keyword: chinavirusprevention

Brevity: Headers | « Text »
  • Mouthwashes may suppress SARS-CoV-2 (Low concentration cetylpyridinium chloride)

    10/06/2022 2:52:01 PM PDT · by ConservativeMind · 25 replies
    SARS-CoV-2, the virus that causes COVID-19, is an airborne disease transmitted via aerosols, which are spread from the oral and nasal cavities—the mouth and the nose. In addition to the well-known division and spread of the virus in the cells of the respiratory tract, SARS-CoV-2 is also known to infect the cells of the lining of the mouth and the salivary glands. Commercially available mouthwashes contain a number of antibiotic and antiviral components that act against microorganisms in the mouth. One of these, cetylpyridinium chloride (CPC), has been shown by a team of researchers led by Professor Kyoko Hida to...
  • New Antiviral Nasal Spray Outperforms Current Antibody Treatments for COVID-19 and Its Variants in Mice

    04/14/2022 10:16:02 AM PDT · by Red Badger · 25 replies
    https://scitechdaily.com ^ | April 14, 2022 | By NORTHWESTERN UNIVERSITY
    Antiviral Nasal Spray A single inhaled dose treated or even prevented infection by COVID-19 and its variants. Current antibody treatments block SARS-CoV-2 by binding to one of three binding sites on the spike protein New antiviral binds to all three sites on the spike protein, making it more effective than current therapies Antiviral is also low-cost, easy to manufacture, does not require complicated supply chains with extreme refrigeration and potentially could be self-administered A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I...
  • Pfizer begins study of oral drug for prevention of COVID-19

    09/27/2021 2:34:24 PM PDT · by MarvinStinson · 69 replies
    aol ^ | September 27, 2021
    Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus. The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG , have been racing to develop an easy-to-administer antiviral pill for COVID-19. The mid-to-late-stage study will test Pfizer's drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection. In the trial, PF-07321332, designed...